SEARCH RESULTS FOR: 得克萨斯A(9271 results)
Equips trained medical first responders with a higher density of the core components identified by the CoTCCC as required to provide lifesaving interventions through buddy-aid and medical aid tasks during the Tactical Field Care phase of care.
• The system is color coded and sequentially organized for rapid visual and muscle
• memory identification of the appropriate tool required under the MARCH protocol.
• The system has an “open architecture” which allows the introduction of emerging technologies that improve the lifesaving capabilities of the individual.
Safeguard US Operating, LLC
01
Not in Commercial Distribution
- M6898444601010 ()
84-446-01
- First aid kit, medicated
Equips trained medical first responders with a higher density of the core components identified by the CoTCCC as required to provide lifesaving interventions through buddy-aid and medical aid tasks during the Tactical Field Care phase of care.
• The system is color coded and sequentially organized for rapid visual and muscle
• memory identification of the appropriate tool required under the MARCH protocol.
• The system has an “open architecture” which allows the introduction of emerging technologies that improve the lifesaving capabilities of the individual.
Safeguard US Operating, LLC
01
Not in Commercial Distribution
- M68984443010 ()
84-443
- First aid kit, medicated
First Aid Kit contained in a metal cabinet. Contents include: 2 Sterile Eyepads; 1oz Eyewash; 0.5" x 5 yd Tape Roll; Antibiotic Ointment Packets, 10 ct; Blue Metal Detectable Fabric Bandages, 1"x 3", 25 ct; Burn Dressing, 4" x 4"; BZK Antiseptic Towelettes, 10ct; Cold Pack, 4" x 5"; First Aid Guide; First Aid Tape, 0.5" x 5 yd, Gauze Roll, 2" x 4 yd; First Aid/Burn Cream Packets, 10 ct; Tweezers: Hand Sanitizer Packets, 10 ct; Nitrile Exam Gloves, 4 ct; Scissors; Sterile Gauze Pads, 3" x 3", 10 ct; Trauma Pads, 5" x 9", 2 ct; Triangular Bandage, CPR Mask
Acme United Corporation
90662
In Commercial Distribution
- 00092265906623 ()
90662
- First aid kit, medicated
First Aid Kit, 16 Unit Metal Kit, meeting ANSI A requirements. Contains:
CPR Face Shield, Scissors , First Aid Tape, 1/2" x 5yd, First Aid Guide, Hand Sanitizer Packets 10ct, Adhesive Fabric Bandages,1" x 3" -16 ct, Triple Antibiotic Ointment packets 12 ct, Antiseptic Wipes 10 ct, First Aid/Burn Cream Packets 12 ct, Burn Dressing, 4" x 4", Cold Pack, 4" x 5", Nitrile Exam Gloves 4 ct, Sterile Gauze Pads, 3" x 3" 4ct, Triangular Bandage, 40" x 40" x 56", Eyewash 1 oz bottle, 2 Eye Pads and Strips, Trauma Pad 5" x 9" (2), Conforming Gauze Rolls, 2" 2 ct
Acme United Corporation
90568
In Commercial Distribution
- 00092265905688 ()
90568
- First aid kit, medicated
First aid kit to treat minor injuries. Packaged in a metal cabinet containing: Triangular sling/bandage, 40" x 40" x 56"; CPR mask with one way valve; Red Cross first aid guide; 25 Adhesive fabric bandages, 1" x 3"; 10 BZK antiseptic towelettes; 10 Antiseptic hand sanitizer packs; 2 First aid tape rolls, 1/2" x 5 yd per roll; Conforming gauze roll, 2" x 4 yd; Cold pack, 4" x 5"; 4 Nitrile gloves; 2 Sterile eye pads & 1 oz eyewash; 10 First aid/burn cream packs, 0.9 gm each; Burn gel dressing, 4" x 4"; 10 Antibiotic ointment packs, 0.9 gm each; 10 Sterile gauze pads, 3" x 3"; 2 Trauma pads, 5" x 9"; Scissors, 1 pair; Stainless steel tweezers, 1 pair
Acme United Corporation
90661
In Commercial Distribution
- 00092265906616 ()
90661
- First aid kit, medicated
The LYHER Novel Coronavirus (2019-nCoV) IgM/IgG Antibody Combo Test Kit (Colloidal Gold) is a lateral flow immunoassay intended for the qualitative detection of and differentiation of IgG and IgM antibodies to SARS-CoV-2 in serum and plasma (dipotassium-EDTA, lithium-heparin, or sodium-citrate). The LYHER Novel Coronavirus (2019-nCoV) IgM/IgG Antibody Combo Test Kit (Colloidal Gold) is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicatingrecent or prior infection. At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C 263a, that meet requirements to perform moderate or high complexity tests.
Hangzhou Laihe Biotech Co.,Ltd.
303002
In Commercial Distribution
- 06972412619405 ()
- SARS-CoV-2 immunoglobulin G (IgG)/IgM antibody IVD, kit, rapid ICT, clinical
The Access SARS-CoV-2 IgG assay is a paramagnetic particle, chemiluminescent immunoassay intended for the qualitative detection of IgG antibodies to SARS-CoV-2 in human serum, serum separator tubes and plasma (lithium heparin, dipotassium EDTA, tripotassium EDTA, and sodium citrate). The Access SARS-CoV-2 IgG assay is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. 263a, that meet requirements to perform moderate or high complexity tests.
The Access SARS-CoV-2 IgG assay is only for use under the Food and Drug Administration's Emergency Use Authorization.
Beckman Coulter, Inc.
C58961
In Commercial Distribution
- 15099590738648 ()
C58961
- SARS-CoV-2 immunoglobulin G (IgG) antibody IVD, kit, chemiluminescent immunoassay
The Access SARS-CoV-2 IgM is a paramagnetic particle, chemiluminescent immunoassay intended for the qualitative detection of IgM antibodies to SARS-CoV-2 in human serum, serum separator tubes and plasma (lithium heparin, dipotassium EDTA, tripotassium EDTA, sodium citrate). The Access SARS-CoV-2 IgM is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity. The Access SARS-CoV-2 IgM should not be used to diagnose acute SARS-CoV-2 infection. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. 263a, that meet requirements to perform moderate or high complexity tests.
The Access SARS-CoV-2 IgM assay is only for use under the Food and Drug Administration's Emergency Use Authorization.
Beckman Coulter, Inc.
C58957
In Commercial Distribution
- 15099590738617 ()
C58957
- SARS-CoV-2 immunoglobulin M (IgM) antibody IVD, kit, chemiluminescent immunoassay
The lmmuView® COVID-19 Antigen Home Test is a lateral flow immunoassay device intended for the qualitative detection of nucleocapsid protein antigen from the SARS-CoV-2 virus.
This test is authorized for non-prescription home use with self-collected anterior nasal (nares) swab samples from individuals aged 14 years or older or adult collected anterior nasal (nares) swab samples from individuals aged two years or older. This test is authorized for individuals with symptoms of COVID-19 within the first 7 days of symptom onset when tested at least twice over three days with at least 48 hours between tests, and for individuals without symptoms or other epidemiological reasons to suspect COVID-19, when tested at least three times over five days with at least 48 hours between tests.
The lmmuView® COVID-19 Antigen Home Test does not differentiate between SARS-CoV and SARS-CoV-2.
Results are for the identification of SARS-CoV-2 nucleocapsid protein antigen, which is generally detectable in anterior nasal (nares) swab specimens during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with past medical history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Individuals who test positive with the lmmuView® COVID-19 Antigen Home Test should self-isolate and seek follow-up care with their physician or healthcare provider as additional testing may be necessary.
All negative results are presumptive and confirmation with a molecular assay, if necessary for patient management, may be performed. Negative results do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control measures such as isolating from others and wearing masks. Negative results should be
CTK BIOTECH INC.
R0182CHT-20T
In Commercial Distribution
- 00855402007979 ()
R0182CHT
- SARS-CoV-2 antigen IVD, kit, rapid ICT, self-testing
The lmmuView® COVID-19 Antigen Home Test is a lateral flow immunoassay device intended for the qualitative detection of nucleocapsid protein antigen from the SARS-CoV-2 virus.
This test is authorized for non-prescription home use with self-collected anterior nasal (nares) swab samples from individuals aged 14 years or older or adult collected anterior nasal (nares) swab samples from individuals aged two years or older. This test is authorized for individuals with symptoms of COVID-19 within the first 7 days of symptom onset when tested at least twice over three days with at least 48 hours between tests, and for individuals without symptoms or other epidemiological reasons to suspect COVID-19, when tested at least three times over five days with at least 48 hours between tests.
The lmmuView® COVID-19 Antigen Home Test does not differentiate between SARS-CoV and SARS-CoV-2.
Results are for the identification of SARS-CoV-2 nucleocapsid protein antigen, which is generally detectable in anterior nasal (nares) swab specimens during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with past medical history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Individuals who test positive with the lmmuView® COVID-19 Antigen Home Test should self-isolate and seek follow-up care with their physician or healthcare provider as additional testing may be necessary.
All negative results are presumptive and confirmation with a molecular assay, if necessary for patient management, may be performed. Negative results do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control measures such as isolating from others and wearing masks. Negative results should be
CTK BIOTECH INC.
R0182CHT-5T
In Commercial Distribution
- 00855402007962 ()
R0182CHT
- SARS-CoV-2 antigen IVD, kit, rapid ICT, self-testing